Showing results (51-60 of 154) with videos related to

Sort By:
Pageof 16
Japanese Journal of Clinical Oncology|June 1, 2007
Serum total bilirubin as a predictive factor for severe neutropenia in lung cancer patients treated with cisplatin and irinotecanYutaka Fujiwara, Ikuo Sekine, Yuichiro Ohe, et al.
Cancer Science|March 18, 2006
Effect of the introduction of minimum lesion size on interobserver reproducibility using RECIST guidelines in non-small cell lung cancer patientsHirokazu Watanabe, Hideo Kunitoh, Seiichiro Yamamoto, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 7, 2002
Contribution of the NQO1 and GSTT1 polymorphisms to lung adenocarcinoma susceptibilityNoriaki Sunaga, Takashi Kohno, Noriko Yanagitani, et al.
Lung Cancer (Amsterdam, Netherlands)|July 15, 2015
Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapyShintaro Kanda, Hidehito Horinouchi, Yutaka Fujiwara, et al.
Medical Oncology (Northwood, London, England)|October 6, 2007
Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patientsKan Yonemori, Hideo Kunitoh, Koji Tsuta, et al.
Japanese Journal of Clinical Oncology|April 25, 2007
Phase I study of cisplatin analogue nedaplatin, paclitaxel, and thoracic radiotherapy for unresectable stage III non-small cell lung cancerIkuo Sekine, Minako Sumi, Yoshinori Ito, et al.
International Journal of Radiation Oncology, Biology, Physics|March 8, 2011
Phase I study of concurrent high-dose three-dimensional conformal radiotherapy with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small-cell lung cancerIkuo Sekine, Minako Sumi, Yoshinori Ito, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 13, 2010
A multi-institution phase I/II trial of triweekly regimen with S-1 plus cisplatin in patients with advanced non-small cell lung cancerKaoru Kubota, Hiroshi Sakai, Nobuyuki Yamamoto, et al.
Japanese Journal of Clinical Oncology|December 20, 2024
Clinical outcomes of patients with EGFR-mutated NSCLC developing interstitial lung disease during first-line osimertinib therapy: a sub-analysis of the Reiwa studyTakayuki Kobayashi, Kageaki Watanabe, Yukio Hosomi, et al.
Japanese Journal of Clinical Oncology|December 20, 2024
Observational study of the efficacy and safety of first-line osimertinib and later treatments for uncommon epidermal growth factor receptor-activating mutation-positive advanced non-small cell lung cancerTsuyoshi Hirata, Kageaki Watanabe, Yukio Hosomi, et al.
Pageof 16